Novo Nordisk $1.1 billion acquisition of Forma Therapeutics
We are advising Novo Nordisk on the transaction
Davis Polk is advising Novo Nordisk on its approximately $1.1 billion acquisition of Forma Therapeutics. Under the terms of the acquisition agreement, Novo Nordisk will initiate a tender offer to acquire all outstanding shares of Forma Therapeutics. The transaction has been unanimously approved by the Forma Therapeutics Board of Directors. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing a majority of Forma Therapeutics’ outstanding shares, receipt of applicable regulatory approvals and other customary conditions. The transaction is expected to close in the fourth quarter of 2022.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, with the purpose to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Forma Therapeutics’ R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need.
The Davis Polk corporate team includes partner William H. Aaronson and associates Alex Yang and Natasha D. Shah. The intellectual property and technology transactions team includes partner David R. Bauer and associates Hilary Smith and Adrian Rabin. The executive compensation team includes partner Veronica M. Wissel and counsel Joseph S. Brown. The antitrust and competition team includes partner Arthur J. Burke. The tax team includes partner William A. Curran. Members of the Davis Polk team are based in the New York and Northern California offices.